Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guideline Platform
  3. Gynaecology
  4. Back
  5. Gynaecology guidelines
  6. Management of Bartholin’s cyst and abscess, Gynaecology (066)
Announcements and latest updates

Right Decision Service newsletter: April 2024

Welcome to the Right Decision Service (RDS) newsletter for April 2024. 

Issues with RDS and Umbraco access

Tactuum has been working hard to address the issues experienced during the last week. They have identified a series of three mitigation measures and put the first of these in place on Friday 3rd May.  If this does not resolve the problems, the second mitigation will be actioned, and then the third if necessary.

Please keep a lookout for any slowing down of the system or getting locked out. Please email myself, mbuchner@tactuum.com and onivarova@tactuum.com if you experience any problems, and also please raise an urgent support ticket via the Support Portal.

Thank you for your patience and understanding while we achieve a full resolution.

Promotion and communication resources

A rotating carousel presenting some of the key RDS tools and capabilities, and an editable slideset, are now available in the Resources for RDS providers section of the Learning and Support toolkit.

Redesign and improvements to RDS

The redesign of RDS Search and Browse is still on-track for delivery by mid-June 2024. We then plan to have a 3-week user acceptance testing phase before release to live. All editors and toolkit owners on this mailing list will be invited to participate in the UAT.

The archiving and version control functionality is also progressing well and we will advise on timescales for user acceptance testing shortly.

Tactuum is also progressing with the deep linking to individual toolkits within the mobile RDS app. There are several unknowns around the time and effort required for this work, which will only become clear as the work progresses. So we need to be careful to protect budget for this purpose.

New feature requests

These have all been compiled and effort estimated. Once the redesign work is complete, these will be prioritised in line with the remaining budget. We expect this to take place around late June.

Evaluation

Many thanks to those of you completed the value and impact survey we distributed in February. Here are some key findings from the 65 responses we received.

Figure 1: Impact of RDS on direct delivery of care

Key figures

  • 93% say that RDS has improved evidence-informed practice (high impact 62%; some impact 31%)
  • 91% report that RDS has improved consistency in practice (high impact 65%, some impact 26%)
  • 85% say that RDS has improved patient safety (high impact 59%, some impact 26%)
  • Although shared decision-making tools are only a recent addition to RDS, and only represent a small proportion of the current toolset, 85% of respondents still said that RDS had delivered impact in this area (53% high impact, 32% some impact.) 92% anticipate that RDS will deliver impact on shared decision-making in future and 85% believe it will improve delivery of personalised care in future.

Figure 2 shows RDS impact to date on delivery of health and care services

 

Key figures

These data show how RDS is already contributing to NHS reform priorities and supporting delivery of more sustainable care.

Saving time and money

  • RDS clearly has a strong impact on saving practitioner time, with 90% of respondents reporting that this is the case. 65% say it has a high impact; 25% say it has some impact on time-saving.
  • It supports devolved decision-making across the multi-professional team (85% of respondents)
  • 76% of respondents confirm that it saves money compared, for example, to investing in commercial apps (54% high impact; 22% some impact.)
  • 72% believe it has impacted already on saving money and reducing waste in the way services are delivered – e.g. reducing costs of referral management, prescribing, admissions.

Quality assurance and governance

  • RDS leads are clear that RDS has improved local governance of guidelines, with 87% confirming that this is the case. (62% high impact; 25% some impact.)

Service innovation and workforce development

  • RDS is a major driver for service innovation and improvement (83% of respondents) and has impacted significantly on workforce knowledge and skills (92% of respondents – 66% high impact; 26% some impact).

New toolkits

A few examples of toolkits published to live in the last month:

Toolkits in development

Some of the toolkits the RDS team is currently working on:

  • SARCS (Sexual Assault Response Coordination Service)
  • Staffing method framework – Care Inspectorate.
  • SIGN 171 - Diabetes in pregnancy
  • SIGN 158 – British Guideline on Management of Asthma. Selected sections will be incorporated into the RDS, and complemented by a new chronic asthma pathway being developed by SIGN, British Thoracic Society and NICE.
  • Clinical pathways from NHS Fife and NHS Lanarkshire

Please contact his.decisionsupport@nhs.scot if you would like to learn more about a toolkit. The RDS team will put you in touch with the relevant toolkit lead.

Quality audit of RDS toolkits

Thanks to all of you who have responded to the retrospective quality audit survey and to the follow up questions.  We still have some following up to do, and to work with owners of a further 23 toolkits to complete responses. An interim report is being presented to the HIS Quality and Performance Committee.

Implementation projects

Eight clinical services and two public library services are undertaking tests of change to implement the Being a partner in my care app. This app aims to support patients and the public to become active participants in Realistic Medicine. It has a strong focus on personalised, person-centred care and a library of shared decision aids, as well as simple explanations and videoclips to help the public to understand the aims of Realistic Medicine.  The tests of change will inform guidance and an implementation model around wider adoption and spread of the app.

With kind regards

Right Decision Service team

Healthcare Improvement Scotland

Management of Bartholin’s cyst and abscess, Gynaecology (066)

Warning

Objectives

To provide guidance on the management of those presenting with and Bartholin’s cyst or abscess

Audience

All healthcare professionals involved in the care of women with a Bartholin’s cysts or abscess

Please report any inaccuracies or issues with this guideline using our online form

The Bartholin’s gland is a mucus secreting gland located bilaterally at the base of the labia minora, at the level of the hymen. When the duct becomes blocked, a cyst may form and the gland may be palpable. If the cyst becomes infected, an abscess may form which can cause severe pain. The life-time risk is approximately 3%. 

Clinical Features

Patients will present with a painful unilateral swelling in the vagina. 

On examination, there will be a tender, erythematous swelling at 4 or 8 o’clock on the lateral vaginal wall. Tracking of the abscess along the vaginal wall may cause cellulitis. 

Differential diagnosis

  • Inclusion cyst
  • Gartner duct cyst
  • Haematoma
  • Sebaceous cyst
  • Lipoma
  • Hidradenitis suppurativa
  • Endometriosis

Investigations

A charcoal swab should be obtained from the cyst/abscess and sent for culture and sensitivity. It is estimated that >70% of cysts are culture sterile, and only 33% of abscess cultures are sterile.

Bartholin’s duct abscesses may be polymicrobial: E. coli (single most common pathogen), followed by infections including Staphylococcus aureus, Group B streptococci and Enterococci species. Neisseria gonorrohoea may be identified.

Additional appropriate swabs should be obtained for chlamydia and gonorrohoea if there is risk of a sexually transmitted infection. 

Biopsy

A biopsy may be indicated in women over 40 years old as there is an increased risk of adenocarcinoma of the Bartholin’s gland. 

Management

This will depend on the severity and the duration of the patient’s symptoms in addition to patient preference.   

Recurrence rates are not consistently reported.  However, one RCT (WoMan trial) summarised that Marsupialisation and Word catheter recurrence at 12 months are similar (10-12%).   Where incision and drainage or needle aspiration is performed, recurrence is thought to be higher, and therefore should be avoided if possible.  The aim should being to create a new mucocutaneous junction between the wall of the cyst and the skin of the labia to allow continued drainage.

Conservative management, no signs of infection

Hot baths several times per day and simple analgesia.  In the absence of cellulitis, antibiotics are not indicated.

Conservative management, no surgical intervention with suggestion of mild infection with presence of cellulitis or offensive discharge.  A review of any previous swabs should be undertaken.

Where antibiotic treatment is required, suggested regimes are

Co-amoxiclav 625mg orally 8 hourly, total duration for 5 days

Or

Co-trimoxazole (Septrin) 960mg orally 12 hourly, total duration for 5 days (avoid 1st trimester pregnancy)

Surgical Management - Word Balloon Catheter

This treatment should be used first line in the surgical management of Bartholin’s cysts or abscesses. This is a very well tolerated procedure and has good operative success. 

The Word catheter kits contain the 3cm long catheter, a syringe for inflation and the scalpel. A local anaesthetic, such as 1% lidocaine, may be used to infiltrate the skin prior to the initial incision being made. Via a 5mm stab incision into the mucosal surface of the labia minora, just exterior to the hymen ring, within the introitus in the region of the normal duct opening. 

A charcoal swab should be obtained from the discharging fluid. 

The catheter is inserted and inflated with a maximum of 3ml of saline, as per the manufacturer’s guidelines. If the balloon is overfilled this may cause extra discomfort so the balloon should be deflated by extracting some saline. If the incision is made too large the catheter may fall out so an anchor suture may be required to hold it in place.

The patient can go home with the catheter in situ and usually this stays in for 4 weeks to encourage formation of an epithelialised fistula and prevent refilling of the abscess. A patient information leaflet should be given with a contact number for the gynaecology emergency service.

After 4 weeks, the catheter is deflated and removed. If the catheter falls out at home during this time it may be left out provided the patient’s symptoms are resolving. 

Where there are no signs of infection, antibiotic cover is not required.

Consideration should be made to cover with broad spectrum antibiotics if signs suggestive of an infection are present e.g. purulent offensive smelling discharge or signs of cellulitis.  A review of any previous swab results should be undertaken.

Where antibiotic treatment is required suggest

Co-amoxiclav 625mg orally 8 hourly, total duration for 5 days

or

Co-trimoxazole (Septrin) 960mg orally 12 hourly, total duration for 5 days (avoid 1st trimester pregnancy)

Surgical Management - Marsupialisation 

Where there is a recurrent abscess or if patient would prefer to avoid Word Catheter insertion, marsupialisation under a general anaesthetic should be performed. The purpose of this is to create a fistula and prevent further abscess formation. Packing is not routinely required. 

In theatre, a single dose of intravenous antibiotic cover should be given.

1.2g of co-amoxiclav, IV

or

900mg of clindamycin, IV

Consideration should be made to continue cover with broad spectrum antibiotics, particularly if signs suggestive of an infection are present e.g. purulent offensive smelling discharge or signs of cellulitis. 

Co-amoxiclav 625mg orally 8 hourly, total duration for 5 days

or

Co-trimoxazole (Septrin) 960mg orally 12 hourly, total duration for 5 days (avoid 1st trimester pregnancy)

Follow up

This is not routinely required after marsupialisation of the cyst or abscess.

If patients have already been commenced on oral antibiotics, they may wish to complete the course. However, they do not routinely need to start treatment after the initial dose in theatre, if there are no signs suggestive of infection.

Simple vulval hygiene advice should include avoiding bubble baths, lotions or talcum powder. Sexual intercourse should be avoided until there is no pain or discharge. 

Editorial Information

Last reviewed: 14/06/2023

Next review date: 16/05/2026

Author(s): Joy SimpsonDr Joy Simpson, Consultant O&G PRM.

Version: 2

Approved By: Gynaecology Clinical Governance Group

Document Id: 066

Related resources
References

Balloon catheter insertion for Bartholin's cyst or abscess | Guidance and guidelines | NICE

Inserting an inflatable balloon to treat a bartholin’s cyst or abscess Interventional Procedure guidance 323. December 2009. National Institute for Health and Clinical Excellence (NICE)

Wechter Wu, Marzano and Haefner. Management of bartholin duct cyst and abscesses. A systematic review. Obstetrical and Gynaecolocal Survey; 64(6) 2009. 

BMJ Best Practice, Bartholin's cyst - Symptoms, diagnosis and treatment, August 2022.

Omole F et al. Bartholin Duct Cyst and Gland Abscess: Office ManagementAm Fam Physician. 2019;99(12):760-766

Kroese AJ et al. Word catheter and marsupialisation in women with a cyst or abscess of the Bartholin gland (WoMan-trial): a randomised clinical trial. BJOG. 2017 Jan;124(2):243-249.